GlassScriptPhysician profile
Anthony Rees
NPI 1104312206
$7,429.59
in general payments reported to CMS, 2019-2025
45 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,439 · 2022: $1,455 · 2023: $1,237 · 2024: $1,744 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,535.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,257.59 | 2021-2025 | |
| Novo Nordisk INC | $1,065.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $758.78 | 2021-2025 | Farxiga, Brilinta, Airsupra |
| Lilly USA, LLC | $461.68 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $412.44 | 2021-2025 | |
| Daiichi Sankyo INC. | $318.60 | 2021-2025 | Injectafer |
| Amgen INC. | $225.38 | 2022-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $223.29 | 2021-2025 | Trintellix, Aralast |
| Janssen Pharmaceuticals, INC | $193.27 | 2021-2024 | Xarelto |
| Mylan Specialty L.P. | $176.93 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $160.58 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $140.90 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $116.68 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $115.14 | 2023-2025 | Gvoke Hypopen |
| Viatris Specialty LLC | $113.90 | 2025 | Yupelri |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.